Kyowa Kirin develops nucleic acid drug for KRAS using proprietary liquid nanoparticles

KRAS is proto-oncogene corresponding to the oncogene first identified in Kirsten rat sarcoma virus,, and the gene product was first found as a p21 GTPase. Kyowa Hakko Kirin works on a nucleic acid medicine in which siRNA, targeting KRAS, is targeted to tumor-specific unique lipid nanoparticles (LNP), and has confirmed potent antitumor effects in animal experiments.

Source: Publication at AsiaTides meeting, Kyoto, on February 28, 2018

Request a quote for deeper information from
contact@asia-tech.eu

© 2018 Window to Japan - Bio 4 Business - Imprint